Know Cancer

forgot password

Positron Emission Tomography in Patients With Breast Cancer

Not Enrolling
Breast Neoplasms

Thank you

Trial Information

Positron Emission Tomography in Patients With Breast Cancer

This is a prospective study evaluating the role of Positron Emission Tomography (PET scan)
in breast cancer. The radiopharmaceutical [18F] 2-deoxyglucose will be used as both an
imaging modality and to evaluate tumor metabolism in patients with breast cancer. Patients
with stage II, stage IIIA or IIIB, or stage IV breast cancer and evaluable disease in the
breast and/or at metastatic sites will be studied. Patients will be injected intravenously
with [18F]2-deoxyglucose and a PET scan conducted over 90 minutes. Examination of the role
of PET scan in assessing the response of breast cancer to chemotherapy, especially in stage
II and stage III patients, will be done. Up to three PET scans within one year may be
performed. Findings by PET scan will be correlated both with those of concurrent imaging
techniques (x-ray, CT scan, MRI, bone scan or mammogram), and with histologic, biochemical,
and flow cytometric information on the tumor, and with findings in subsequent surgical
specimens. Changes in tumor glucose metabolism with treatment will be assessed by PET
imaging studies and by biochemical methods when possible.

Inclusion Criteria

Histologically proven invasive carcinoma of the breast.

Patients with stage II, stage IIIA or IIIB, or stage IV breast cancer who have not
received local therapy to the breast or axillary lymph nodes.

Evaluable tumor, either gross or microscopic, at locoregional and/or distant sites.

No current pregnancy.

No second invasive malignancy in addition to breast cancer.

No significant concurrent medical disorders (cardiac, renal, hepatic).

Type of Study:


Study Design:



United States: Federal Government

Study ID:




Start Date:

May 1994

Completion Date:

April 2000

Related Keywords:

  • Breast Neoplasms
  • Cancer Diagnosis
  • Cancer Metabolism
  • FDG
  • FDG Breast Imaging
  • PET
  • Positron Emission Mammography
  • Radiopharmaceutical
  • Scintimammography
  • Breast Neoplasms
  • Neoplasms



National Cancer Institute (NCI) Bethesda, Maryland  20892